Patent ID: 11964003
Assignee: XERIS PHARMACEUTICALS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 0:
1. A storage stable sustained release therapeutic formulation comprising:
(a) at least one therapeutic agent, which is selected from a glucagon peptide, glucagon analog, glucagon mimetic, or salt thereof;
(b) at least one ionization stabilizing excipient, which is a mineral acid;
(c) at least one sustained release modifier, which is a divalent cation-donating compound; and
(d) an aprotic polar solvent, which is dimethyl sulfoxide (DMSO),
wherein said formulation is storage stable for at least six months at 25° C. and wherein said formulation, when administered to a patient, results in the presence of therapeutic levels of said therapeutic agent in the blood of said patient for an extended period of time relative to an immediate release formulation comprising the same therapeutic agent.